Astrid Thuerigen - Novartis Pharma AG

基本信息

浏览量：0

职业迁徙

个人简介

暂无内容

研究兴趣

论文共 15 篇作者统计合作学者相似作者

按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选

Abstract PS02-01: Efficacy, safety, and quality of life with ribociclib + endocrine therapy in elderly patients with HR+/HER2– advanced breast cancer across the MONALEESA-2, -3, and -7 trials

Lowell Hart,Seock-Ah Im,Sara Tolaney,Mario Campone,Timothy Pluard,Berta Sousa,Gilles Freyer, Thomas Decker,Kevin Kalinsky,Astrid Thuerigen,Melissa Gao,Huilin Hu,Sherko Küemmel

Cancer Researchno. 9_Supplement (2024): PS02-01

引用0浏览0引用

Efficacy, Safety, and Quality of Life with Ribociclib Plus Endocrine Therapy in Elderly Patients with HR+/HER2-advanced Breast Cancer Across the MONALEESA-2,-3, And-7 Trials

Lowell Hart, Seock-Ah Im,Sara Tolaney, Mario Campone,Timothy Pluard, Berta Sousa, Gilles Freyer,Thomas Decker, Kevin Kalinsky,Astrid Thuerigen, Melissa Gao, Huilin Hu,Sherko Kuemmel

CANCER RESEARCHno. 9 (2024)

引用0浏览0引用

Supplemental Figure 1 from Intrinsic Subtype and Overall Survival of Patients with Advanced HR+/HER2− Breast Cancer Treated with Ribociclib and ET: Correlative Analysis of MONALEESA-2, -3, -7

Aleix Prat,Nadia Solovieff,Fabrice André, Joyce O’Shaughnessy,David Cameron,Wolfgang Janni,Gabe S. Sonke,Yoon‐Sim Yap,Denise A. Yardley,Ann H. Partridge,Astrid Thuerigen,Juan Pablo Zarate,Agnes Lteif,Fei Su,Lisa A. Carey

openalex（2024）

引用0浏览0引用

Supplemental Table 1 from Intrinsic Subtype and Overall Survival of Patients with Advanced HR+/HER2− Breast Cancer Treated with Ribociclib and ET: Correlative Analysis of MONALEESA-2, -3, -7

Aleix Prat,Nadia Solovieff,Fabrice Andrè, Joyce O’Shaughnessy,David Cameron,Wolfgang Janni,Gabe S. Sonke,Yoon‐Sim Yap,Denise A. Yardley,Ann H. Partridge,Astrid Thuerigen,Juan Pablo Zarate,Agnes Lteif,Fei Su,Lisa A. Carey

openalex（2024）

引用0浏览0引用

Supplemental Table 3 from Intrinsic Subtype and Overall Survival of Patients with Advanced HR+/HER2− Breast Cancer Treated with Ribociclib and ET: Correlative Analysis of MONALEESA-2, -3, -7

openalex（2024）

引用0浏览0引用

openalex（2024）

引用0浏览0引用

Intrinsic Subtype and Overall Survival of Patients with Advanced HR+/HER2- Breast Cancer Treated with Ribociclib and ET: Correlative Analysis of MONALEESA-2,-3,-7

Aleix Prat,Nadia Solovieff,Fabrice Andre,Joyce O'Shaughnessy,David A. Cameron,Wolfgang Janni,Gabe S. Sonke,Yoon-Sim Yap,Denise A. Yardley,Ann H. Partridge,Astrid Thuerigen,Juan Pablo Zarate,Agnes Lteif,Fei Su,Lisa A. Carey

Clinical cancer research an official journal of the American Association for Cancer Researchno. 4 (2024): 793-802

引用0浏览0WOS引用

Supplemental Table 2 from Intrinsic Subtype and Overall Survival of Patients with Advanced HR+/HER2− Breast Cancer Treated with Ribociclib and ET: Correlative Analysis of MONALEESA-2, -3, -7

Aleix Prat,Nadia Solovieff,Fabrice André,Joyce O’Shaughnessy,David Cameron,Wolfgang Janni,Gabe S. Sonke,Yoon‐Sim Yap,Denise A. Yardley,Ann H. Partridge,Astrid Thuerigen,Juan Pablo Zarate,Agnes Lteif,Fei Su,Lisa A. Carey

openalex

引用0浏览0引用

openalex（2024）

引用0浏览0引用

Supplemental Figure 1 from Intrinsic Subtype and Overall Survival of Patients with Advanced HR⁺/HER2⁻ Breast Cancer Treated with Ribociclib and ET: Correlative Analysis of MONALEESA-2, -3, -7

Aleix Prat,Nadia Solovieff,Fabrice André, Joyce O'Shaughnessy,David A. Cameron,Wolfgang Janni,Gabe S. Sonke,Yoon-Sim Yap,Denise A. Yardley,Ann H. Partridge,Astrid Thuerigen,Juan Pablo Zarate,Agnes Lteif,Fei Su,Lisa A. Carey

crossref（2024）

引用0浏览0引用

加载更多

作者统计

合作学者

合作机构

D-Core

合作者
学生
导师

暂无相似学者，你可以通过学者研究领域进行搜索筛选

数据免责声明

页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果，我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问，可以通过电子邮件方式联系我们：report@aminer.cn